menu

MENU

繁體中文

Contact Us

Menu

Menu

Company

Introduction
Team & Board of Directors
Partners
Investors
Latest News

R&D Pipeline

Overview
Intranasal Vaccines
Asthma Immunotherapy
Respiratory Antiviral Immunotherapy

Company

Introduction

Team & Board of Director

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Contact us

Latest News

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form

November 23, 2020

【公告】昱厚生技委託臺北醫學大學執行「LTh(αk)應用於氣喘與過敏性鼻炎免疫調控機轉研究計畫」之產學合作

Press

October 8, 2020

【經濟日報】昱厚 將開發新冠疫苗

Press

October 7, 2020

【環球生技月刊】昱厚取國衛院抗原技術授權 開發鼻噴新冠疫苗 股價漲4%

Press

October 6, 2020

Advagene Obtains Technology License from the National Health Research Institutes (NHRI) for "Development of SARS-CoV-2 Antigen Using Influenza Virus-Like Particle Platform" to Combine with Its Proprietary Mucosal Adjuvant Technology.

Updates

August 5, 2020

Advagene Certified as a Biotech and New Pharmaceutical Company by the Ministry of Economic Affairs Under the Act for the Development of Biotech and New Pharmaceuticals Industry.

Updates